Filing Details

Accession Number:
0001209191-15-070343
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-09-11 16:37:18
Reporting Period:
2015-09-09
Filing Date:
2015-09-11
Accepted Time:
2015-09-11 16:37:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1347178 Vanda Pharmaceuticals Inc. VNDA Pharmaceutical Preparations (2834) 030491827
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1355537 Hristos Mihael Polymeropoulos 2200 Pennsylvania Avenue
Suite 300E
Washington DC 20037
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-09-09 42,747 $4.73 800,894 No 4 M Direct
Common Stock Disposition 2015-09-09 29,577 $12.51 771,317 No 4 S Direct
Common Stock Acquisiton 2015-09-10 147,626 $4.73 918,943 No 4 M Direct
Common Stock Disposition 2015-09-10 102,162 $12.73 816,781 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2015-09-09 42,747 $0.00 42,747 $4.73
Common Stock Employee Stock Option (Right to Buy) Disposition 2015-09-10 147,626 $0.00 147,626 $4.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
147,626 2015-12-19 No 4 M Direct
0 2015-12-19 No 4 M Direct
Footnotes
  1. Represents shares of common stock sold to cover the payment of the option exercise price and to satisfy tax obligations relating to exercise of the option, which is scheduled to expire on December 19, 2015.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.87, inclusive.
  4. Became exercisable with respect to 25% of the shares on December 29, 2006 and with respect to an additional 2.08333% of the aggregate shares each month thereafter.